Influenzavirus B Infections - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Influenzavirus B Infections - Pipeline Review, H2 2018’, provides an overview of the Influenzavirus B Infections pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Influenzavirus B Infections, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Influenzavirus B Infections and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Influenzavirus B Infections

- The report reviews pipeline therapeutics for Influenzavirus B Infections by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Influenzavirus B Infections therapeutics and enlists all their major and minor projects

- The report assesses Influenzavirus B Infections therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Influenzavirus B Infections

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Influenzavirus B Infections

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Influenzavirus B Infections pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Adimmune Corp

Altravax Inc

Amarillo Biosciences Inc

Aphios Corp

AstraZeneca Plc

AusBio Ltd

Biotron Ltd

Cocrystal Pharma Inc

ContraFect Corp

Daiichi Sankyo Co ...

AbbVie Inc

Adimmune Corp

Altravax Inc

Amarillo Biosciences Inc

Aphios Corp

AstraZeneca Plc

AusBio Ltd

Biotron Ltd

Cocrystal Pharma Inc

ContraFect Corp

Daiichi Sankyo Co Ltd

e-Therapeutics Plc

Evotec AG

GC Pharma

GlaxoSmithKline Plc

Inovio Pharmaceuticals Inc

Kineta Inc

Medicago Inc

MedImmune LLC

Novavax Inc

Romark Laboratories LC

Sanofi

Sanofi Pasteur SA

Seqirus Ltd

Shionogi & Co Ltd

Sinovac Biotech Ltd

Therapeutic Systems Research Laboratories Inc

Toyama Chemical Co Ltd

Vaxart Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 5

Influenzavirus B Infections – Overview 6

Influenzavirus B Infections – Therapeutics Development 7

Influenzavirus B Infections ...

Table of Contents

Table of Contents 2

Introduction 5

Influenzavirus B Infections – Overview 6

Influenzavirus B Infections – Therapeutics Development 7

Influenzavirus B Infections – Therapeutics Assessment 16

Influenzavirus B Infections – Companies Involved in Therapeutics Development 24

Influenzavirus B Infections – Drug Profiles 38

Influenzavirus B Infections – Dormant Projects 105

Influenzavirus B Infections – Discontinued Products 107

Influenzavirus B Infections – Product Development Milestones 108

Appendix 117

List of Tables

List of Tables

Number of Products under Development for Influenzavirus B Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Tables

Number of Products under Development for Influenzavirus B Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Influenzavirus B Infections – Pipeline by AbbVie Inc, H2 2018

Influenzavirus B Infections – Pipeline by Adimmune Corp, H2 2018

Influenzavirus B Infections – Pipeline by Altravax Inc, H2 2018

Influenzavirus B Infections – Pipeline by Amarillo Biosciences Inc, H2 2018

Influenzavirus B Infections – Pipeline by Aphios Corp, H2 2018

Influenzavirus B Infections – Pipeline by AstraZeneca Plc, H2 2018

Influenzavirus B Infections – Pipeline by AusBio Ltd, H2 2018

Influenzavirus B Infections – Pipeline by Biotron Ltd, H2 2018

Influenzavirus B Infections – Pipeline by Cocrystal Pharma Inc, H2 2018

Influenzavirus B Infections – Pipeline by ContraFect Corp, H2 2018

Influenzavirus B Infections – Pipeline by Daiichi Sankyo Co Ltd, H2 2018

Influenzavirus B Infections – Pipeline by e-Therapeutics Plc, H2 2018

Influenzavirus B Infections – Pipeline by Evotec AG, H2 2018

Influenzavirus B Infections – Pipeline by GC Pharma, H2 2018

Influenzavirus B Infections – Pipeline by GlaxoSmithKline Plc, H2 2018

Influenzavirus B Infections – Pipeline by Inovio Pharmaceuticals Inc, H2 2018

Influenzavirus B Infections – Pipeline by Kineta Inc, H2 2018

Influenzavirus B Infections – Pipeline by Medicago Inc, H2 2018

Influenzavirus B Infections – Pipeline by MedImmune LLC, H2 2018

Influenzavirus B Infections – Pipeline by Novavax Inc, H2 2018

Influenzavirus B Infections – Pipeline by Romark Laboratories LC, H2 2018

Influenzavirus B Infections – Pipeline by Sanofi, H2 2018

Influenzavirus B Infections – Pipeline by Sanofi Pasteur SA, H2 2018

Influenzavirus B Infections – Pipeline by Seqirus Ltd, H2 2018

Influenzavirus B Infections – Pipeline by Shionogi & Co Ltd, H2 2018

Influenzavirus B Infections – Pipeline by Sinovac Biotech Ltd, H2 2018

Influenzavirus B Infections – Pipeline by Therapeutic Systems Research Laboratories Inc, H2 2018

Influenzavirus B Infections – Pipeline by Toyama Chemical Co Ltd, H2 2018

Influenzavirus B Infections – Pipeline by Vaxart Inc, H2 2018

Influenzavirus B Infections – Dormant Projects, H2 2018

Influenzavirus B Infections – Dormant Projects, H2 2018 (Contd..1), H2 2018

Influenzavirus B Infections – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Influenzavirus B Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of ...

List of Figures

Number of Products under Development for Influenzavirus B Infections, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Mechanism of Actions, H2 2018

Number of Products by Stage and Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports